Glypican-3 (GPC3) is a membrane-bound heparan sulfate proteoglycan that is mutated in the SimpsonGolabi-Behmel syndrome. This is an X-linked condition characterized by overgrowth, and various visceral and skeletal dysmorphisms. The phenotype of the SimpsonGolabi-Behmel syndrome patients and GPC3-de®cient mice, as well as gene transfection experiments indicate that GPC3 can act as an inhibitor of cell proliferation and survival. It has been previously shown that GPC3 expression is downregulated in mesotheliomas and ovarian cancer. Here we report that GPC3 expression is also silenced in human breast cancer, and that this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines. Collectively, these data suggest that GPC3 can act as a negative regulator of breast cancer growth. Oncogene (2001) 20, 7408 ± 7412.
Glypicans are a family of heparan sulfate proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol anchor (Bern®eld et al., 1999; Filmus et al., 2000; Filmus, 2001) . Glypican-3 (GPC3), a member of the glypican family, is mutated in patients with the Simpson-Golabi-Behmel syndrome (SGBS) . This is an X-linked condition characterized by pre-and postnatal overgrowth, and a broad spectrum of clinical manifestations that vary from a mild phenotype in carrier females to infantile lethal forms in some males (Behmel et al., 1984; Garganta et al., 1992; Golabi et al., 1984; Neri et al., 1998) . The list of abnormalities observed in SGBS patients can include a distinct facial appearance, and malformations involving craniofacial development (macroglossia, cleft lip/palate, dental malocclusion), chest/skeleton (polydactyly, syndactyly, supernumerary nipples, supernumerary ribs), genitalia (hypospadias, cryptorchidism), and internal organs (cardiac defects, diaphragmatic hernias, renal cystic dysplasia) (Garganta et al., 1992; Hughes-Benzie et al., 1996; Neri et al., 1998 ). An increased risk for the development of pediatric tumors has also been reported (HughesBenzie et al., 1992) .
The phenotype of SGBS patients and of GPC3-de®cient mice (Cano-Gauci et al., 1999) suggests that during development GPC3 can act as an inhibitor of cell proliferation, and as an inducer of apoptosis in speci®c tissues. Experimental evidence has been provided supporting such a role for GPC3 in various cell lines (Duenas Gonzales et al., 1998) .
Currently, the mechanism by which GPC3 regulates cell proliferation and survival is not clear. It has been proposed that GPC3 can act as a negative regulator of insulin-like growth factor II , but this remains to be proven. There is also genetic evidence that, at least in certain tissues, GPC3 can regulate bone morphogenetic factors (Grisaru et al., 2001; PaineSaunders et al., 2000) , but it seems unlikely that this regulation is the direct cause of the overgrowth observed in GPC3 patients.
It has been recently reported that GPC3 expression is downregulated in mesotheliomas and ovarian cancer (Lin et al., 1999; Murthy et al., 2000) . This ®nding is consistent with the fact that GPC3 can act as a negative regulator of cell proliferation and survival, since cancer cells tend to have an increased proliferation rate, and a reduced sensitivity to apoptosis.
The study on ovarian cancer demonstrated frequent silencing of GPC3 expression in cell lines (Lin et al., 1999) . In all the cases in which GPC3 expression was inhibited, the GPC3 promoter was hypermethylated, and expression was restored by treatment with a demethylating agent. The study on mesotheliomas reported similar results. In this case the silencing of GPC3 expression was also demonstrated in primary tumors (Murthy et al., 2000) . No mutations in the coding region of the GPC3 gene were found either in the ovarian tumors or in the mesotheliomas. In this regard it is important to note that since GPC3 is an Xlinked gene, the silencing of a single allele is enough for complete inhibition of expression .
In the adult, GPC3 is expressed only in a few tissues including mesothelia, and the ovarian and mammary epithelia (Filmus, unpublished results) . We decided, therefore, to investigate whether, like in ovarian cancer and mesothelioma, GPC3 expression is also downregulated in mammary cancer.
To assess GPC3 expression in normal mammary epithelium and in mammary cancer, we performed in situ hybridization in tissue sections that contained both normal and malignant tissue. In all of the 12 patients that were studied GPC3 expression was lower in the tumor cells than in the adjacent normal epithelium. Moreover, in seven of these patients GPC3 expression was undetectable in the tumor cells. Figure 1 shows the results obtained with three typical patients, including a case with cancer in situ. The number of samples studied was insucient to establish a correlation between the degree of downregulation of GPC3 expression and tumor stage.
Next, we investigated whether GPC3 expression is downregulated in breast cancer as a result of promoter hypermethylation, as it was described for ovarian cancer and mesotheliomas (Lin et al., 1999; Murthy et al., 2000) . To select the appropriate cell lines to perform this study, we assessed GPC3 expression in 10 breast cancer cell lines by Northern blot analysis. Since GPC3 expression was undetectable in all of them (data not shown), we decided to perform RT ± PCR, a more sensitive method. This analysis showed that GPC3 expression can be detected in ®ve of the 10 cell lines tested (Figure 2a) .
To assess the methylation status of the GPC3 promoter in the breast cancer cell lines, their genomic (a,c,e) Parallel sections were stained with hematoxylin-eosin. GPC3 sense and anti-sense probes were prepared from Bluescript KS-plasmids (Stratagene) containing the 594 bp PstI and HindIII fragment of the human GPC3 cDNA in the sense and anti-sense orientations. The RNA probes were synthesized by in vitro transcription in the presence of digoxigeninlabeled UTP (Roche) with the use of T3 and T7 RNA polymerase (Promega) following the protocol recommended by the company. In situ hybridization was performed as described previously (Xiang et al., 1994) . GPC3 expression was detected in normal mammary epithelial cells in (b, right side), and (f, arrow), whereas tumor cells are negative (d,f) or weakly positive in non-invasive cancer (b, left side). Scattered positive cells within the tissue sections are in®ltrating lymphocytes Figure 2 Expression and DNA methylation analysis of GPC3. (a) RT ± PCR analysis of GPC3 expression. One mg of total RNA isolated from the hepatocarcinoma cell line HepG2 (GPC3 positive control), and the breast carcinoma cell lines was reverse transcribed using SuperScript TM RNase H 7 (GIBCO BRL), and ampli®ed by using primers speci®c for GPC3 (upstream: 5'-CCAACATGCTGCTCAAGAAAGATGGAAG-3', downstream: 5'CAAACTCAAAAGCTTGTGGAGTCAGGCT-3'), and for bactin (upstream: 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3', downstream: 5'-CTAGAAGCATTTGCGGTGGAC-GATGGAGGG-3'). PCR was performed for 35 cycles (denaturation at 948C, 1 min; annealing at 528C, 1 min; elongation at 728C, 1 min; with a ®nal extension cycle at 728C, 5 min). b-actin RT ± PCR product provides a control for the amount of intact RNA used in the reactions (bottom). The expected ampli®cation products for GPC3 (226 bp) and b-actin (661 bp) are indicated. (b) Schematic drawing of the 5' region of the GPC3 gene encompassing part of the promoter, the ®rst exon, and part of the ®rst intron. The location of the 247 bp fragment used as a probe for Southern blot analysis, and the size of the expected DNA fragments are indicated. (c) DNA methylation analysis. Twenty mg of genomic DNA were digested with EcoRI (E), or with EcoRI and EagI (EE). Digested DNA was analysed by Southern blot using the GPC3 probe shown in (b). The expected 8.0-kb and 4.2-kb fragments corresponding to the methylated and non-methylated states of the GPC3 promoter, respectively, are indicated Figure 3 Reexpression of GPC3 after demethylation. Tumor cell lines MDA-MB-231 and MDA-MB-435 were treated with 5 mM 5-aza-2'-deoxycitidine (Sigma) for 4 days. The medium was replenished every day. (a) The eect of the treatment on the methylation status of the EagI site was assessed by Southern blot as described in Figure 2. (b) GPC3 expression before and after treatment was analysed by RT ± PCR as described in Figure 2 DNA was digested with EcoRI alone, or with EcoRI and EagI. Both enzymes cut within the CpG island located in the GPC3 promoter region, and EagI is methylation-sensitive (Figure 2b ). It has been previously reported that the methylation of the EagI site of the GPC3 promoter correlates well with expression (Lin et al., 1999) . The sensitivity of the genomic DNA to digestion with EcoRI, and a combination of EcoRI and EagI was assessed by Southern blot analysis, using as probe a DNA fragment that can detect both possible products of the digestion (Figure 2b ). As shown in Figure 2c , three cell lines (MDA-MB-231, MDA-MB-435, and Hs578T) displayed complete methylation of the EagI site. As expected, GPC3 was not expressed in these cell lines (Figure 2a) . On the other hand, the ®ve cell lines that expressed GPC3 displayed signi®cant amounts of a 4.2 Kb band, which is the expected size when the genomic DNA is not methylated at the EagI site (Lin et al., 1999) . In the case of MDA-MB-468 and BT-549, DNA digestion also generated a 4.2 Kb band despite the fact that these cell lines do not show any detectable GPC3 expression. To investigate the possibility that in these two cell lines other sites within the GPC3 promoter have been subjected to methylation, we performed Southern blot analysis using BssHII, another methylation-sensitive enzyme that demonstrated an aberrant methylation pattern in the GPC3 promoter of mesothelioma cell lines (Murthy et al., 2000) . This analysis showed that both MDA-MB-468 and BT-549 also display aberrant methylation of the GPC3 promoter (data not shown).
Since GPC3 is located on the X chromosome, in females one of the two alleles is inactivated by methylation in normal somatic tissues . Thus, one would expect to see in all breast cancer cell lines the presence of the 8 Kb band corresponding to the methylated GPC3 allele. It is interesting to note, however, that in two cell lines (MDA-MB-157 and T47D) this band was not detected. It is possible, therefore, that in these tumors the inactive allele has been lost during progression of the disease.
To determine whether the methylation of the GPC3 promoter can play a role in the silencing of GPC3 expression, we treated the GPC3-negative cell lines that showed complete methylation of the EagI site (MDA-MB-231 and MDA-MB-435) with the demethylating agent 5-aza-2'-deoxycytidine. As shown in Figure 3b , such treatment was able to restore GPC3 expression in both cell lines. This was accompanied by demethylation of the EagI site, as determined by Southern blot analysis (Figure 3a) . Treatment with 5-aza-2'-deoxycitidine also restored GPC3 expression in the MDA-MB-468 and BT-549 cell lines, which displayed an abnormal pattern of methylation after digestion with BssHII (data not shown). We conclude therefore that, like in ovarian cancer and mesotheliomas, promoter hypermethylation is at least one of the mechanisms by which GPC3 expression is silenced in breast cancer.
By using a colony-forming eciency assay we have previously shown that GPC3 can inhibit growth in the breast cancer cell line MCF-7 (Duenas Gonzales et al., 1998) . To investigate whether this growth-inhibitory activity is a general feature of breast cancer we performed the colony-forming eciency assay in all the cell lines included in this study. When compared with vector control, an expression vector containing GPC3 signi®cantly inhibited colony formation in eight out of the 10 cell lines (Table 1) . Thus, although the growth-inhibitory eect of GPC3 is not restricted to MCF-7 cells, it is not a general feature of all breast cancer cells. It is well established that tumor cell lines carry numerous mutations, and that some of these mutations can aect signaling pathways of speci®c growth factors, inducing growth-factor independence. We speculate that the lack of growth-inhibitory activity of GPC3 in MDA-MB-231 and MDA-MB-435 indicates that the particular growth factor signaling system with which GPC3 interacts is not functioning properly in these speci®c cell lines.
In conclusion, we have shown here that GPC3 expression is silenced in breast cancer, and that in most cases this silencing is due, at least in part, to promoter hypermethylation. Since ectopic expression of GPC3 can inhibit cell growth of a signi®cant proportion of breast cancer cell lines, collectively our results suggest that GPC3 can be considered a negative regulator for breast cancer growth. An expression vector carrying the human GPC3 cDNA, or the vector alone were transfected into the indicated cell lines by using Lipofectin, as previously described (Duenas Gonzales et al., 1998) . Transfected cells were then selected in the presence 600 mg/ml geneticin, and surviving colonies were counted 14 days later. The number of colonies obtained with vector alone was considered 100%. The results represent the average of duplicates. The experiment was repeated using dierent batches of DNA, and the results were similar
